Please Wait.....
Report
Global Cyclophosphamide Drug Market Report and Forecast 2023-2031
Market Report I 2023-04-04 I 147 Pages I EMR Inc.
Global Cyclophosphamide Drug Market Report and Forecast 2023-2031
Global Cyclophosphamide Drug Market Outlook
The global cyclophosphamide drug market is projected to grow at a CAGR of 2.2% during the forecast period of 2023-2031, reaching a value of USD 806 million by 2031. The market growth can be attributed to the increasing prevalence of cancer and autoimmune diseases, as well as the rising demand for effective treatments.
Global Cyclophosphamide Drug Market: Introduction
Cyclophosphamide is a chemotherapy drug and immunosuppressive agent used to treat various types of cancer and autoimmune diseases. It works by interfering with the growth and spread of cancer cells and suppressing the immune system. The increasing prevalence of cancer and autoimmune diseases, such as lupus and rheumatoid arthritis, is driving the demand for cyclophosphamide drugs. Other factors, such as advancements in drug delivery methods, improving healthcare infrastructure, and the growing demand for targeted therapies, are also expected to drive market growth.
Global Cyclophosphamide Drug Market: Epidemiology
Cancer is one of the leading causes of death globally. According to the World Health Organization, in 2022, there were approximately 19.3 million new cancer cases and 10 million cancer-related deaths worldwide. The most common types of cancer include breast, lung, prostate, and colorectal cancer. The increasing prevalence of cancer is driving the demand for effective treatments, including chemotherapy drugs like cyclophosphamide.
Autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, are also on the rise. These diseases occur when the immune system mistakenly attacks healthy cells in the body, leading to inflammation and damage to various organs and tissues. The growing prevalence of autoimmune diseases is further driving the demand for immunosuppressive drugs, such as cyclophosphamide.
Cyclophosphamide Drug Market Segmentations
The market can be segmented based on route of administration, dose, diseases, distribution channel, and region:
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Dose
- High Dose
- Low Dose
Market Breakup by Disease
- Oncology
- Autoimmune Diseases
- AL Amyloidosis
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Region
- North America
? United States of America
? Canada
- Europe
? United Kingdom
? Germany
? France
? Italy
? Others
- Asia Pacific
? China
? Japan
? India
? ASEAN
? Australia
? Others
- Latin America
? Brazil
? Argentina
? Mexico
? Others
- Middle East and Africa
? Saudi Arabia
? United Arab Emirates
? Nigeria
? South Africa
? Others
Cyclophosphamide Drug Market Analysis
North America is currently the largest market for cyclophosphamide drugs, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of cancer and autoimmune diseases, a well-established healthcare infrastructure, and strong investment in research and development. Europe is also a significant market for cyclophosphamide drugs, with countries such as the UK, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of cancer and autoimmune diseases, and government initiatives to address healthcare concerns. Additionally, the region has a well-established healthcare system, which supports the delivery of effective treatments.
Asia Pacific is another region that is experiencing significant growth in the cyclophosphamide drug market. The region's market growth is driven by factors such as a large population base, increasing awareness of cancer and autoimmune diseases, and the growing adoption of advanced treatment options. In addition, government initiatives to address healthcare concerns are helping to drive the growth of the market in the region.
Latin America and the Middle East and Africa are also witnessing growth in the cyclophosphamide drug market. This growth is primarily driven by the rising prevalence of cancer and autoimmune diseases, improvements in healthcare infrastructure, and increasing government support for healthcare initiatives.
Key Players in the Global Cyclophosphamide Drug Market
The report provides a detailed analysis of the key players involved in the cyclophosphamide drug market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
- Baxter Laboratories Ltd.
- Novartis AG
- Himka Pharmaceuticals Plc.
- Amneal Pharmaceuticals LLC
- NorthStar Rx LLC
- Aurobindo Pharma Ltd.
- CSC Pharmaceutical International
- Jiangsu Hengrui Medicine Co Ltd
- Nodus Oncology
- Abbive, Inc.
- Theravance Biopharm, Inc.
- Sanofi S.A.
- Roxane Laboratories Pvt Ltd
- LGM Pharma Llc
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Cyclophosphamide Drug Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Investment Scenarios
6.5 Regulatory Framework
6.5.1 Regulatory Overview
6.5.1.1 US FDA
6.5.1.2 EU EMA
6.5.1.3 INDIA CDSCO
6.5.1.4 JAPAN PMDA
6.5.1.5 Others
7 Challenges and Unmet Need
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Rate
7.3 Awareness and Prevention Gaps
8 Global Cyclophosphamide Drug Market
8.1 Global Cyclophosphamide Drug Market Overview
8.2 Global Cyclophosphamide Drug Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Cyclophosphamide Drug Market Historical Value (2016-2022)
8.2.1.2 Global Cyclophosphamide Drug Market Forecast Value (2023-2031)
8.3 Global Cyclophosphamide Drug Market by Route of Administration
8.3.1 Market Overview
8.3.1.1 Oral
8.3.1.2 Parenteral
8.4 Global Cyclophosphamide Drug Market by Dose
8.4.1 Market Overview
8.4.1.1 High Dose
8.4.1.2 Low Dose
8.5 Global Cyclophosphamide Drug Market by Disease
8.5.1 Market Overview
8.5.1.1 Cancer Disease
8.5.1.2 Autoimmune Disease
8.5.1.3 AL Amyloidosis
8.5.1.4 Others
8.6 Global Cyclophosphamide Drug Market by Distribution Channel
8.6.1 Market Overview
8.6.1.1 Hospital Based Pharmacies
8.6.1.2 Online Pharmacies
8.6.1.3 Retail Pharmacies
8.7 Global Cyclophosphamide Drug Market by Region
8.7.1 Market Overview
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 North America Cyclophosphamide Drug Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Cyclophosphamide Drug Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Cyclophosphamide Drug Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Cyclophosphamide Drug Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Cyclophosphamide Drug Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Cyclophosphamide Drug Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Drug Adoption Parameters
14.4 Porter's Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Baxter Laboratories Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievement
15.1.4 Merger and Acquisitions
15.1.5 Certifications
15.2 Novartis AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievement
15.2.4 Merger and Acquisitions
15.2.5 Certifications
15.3 Hikma Pharmaceuticals Plc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievement
15.3.4 Merger and Acquisitions
15.3.5 Certifications
15.4 Amneal Pharmaceuticals Llc
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievement
15.4.4 Merger and Acquisitions
15.4.5 Certifications
15.5 NorthStar Rx Llc
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievement
15.5.4 Merger and Acquisitions
15.5.5 Certifications
15.6 Aurobindo Pharma Ltd.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievement
15.6.4 Merger and Acquisitions
15.6.5 Certifications
15.7 CSC Pharmaceuticals International
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievement
15.7.4 Merger and Acquisitions
15.7.5 Certifications
15.8 Jiangsu Hengrui Medicine Co Ltd
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievement
15.8.4 Merger and Acquisitions
15.8.5 Certifications
15.9 Nodus Oncology
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievement
15.9.4 Merger and Acquisitions
15.9.5 Certifications
15.10 Abbive, Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievement
15.10.4 Merger and Acquisitions
15.10.5 Certifications
15.11 Theravance Biopharma, Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievement
15.11.4 Merger and Acquisitions
15.11.5 Certifications
15.12 Sanofi S.A.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievement
15.12.4 Merger and Acquisitions
15.12.5 Certifications
15.13 Roxane Laboratories Pvt Ltd
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievement
15.13.4 Merger and Acquisitions
15.13.5 Certifications
15.14 LGM Pharma Llc
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievement
15.14.4 Merger and Acquisitions
15.14.5 Certifications
16 Pricing Models and Strategies (Additional Insight)
16.1 Cost Model
16.1.1 Manufacturing Cost Analysis
16.1.2 Procurement Cost Analysis
16.2 Pricing Strategies
16.2.1 Competitor Pricing Analysis
16.2.2 Key Assessment of Product Attributes
16.2.3 Pricing Benchmark
17 Global Cyclophosphamide Market- Drug Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security